Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. (Q48414772)
Jump to navigation
Jump to search
scientific article published on 14 September 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. |
scientific article published on 14 September 2012 |
Statements
1 reference
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. (English)
1 reference
Wouter W de Herder
1 reference
Larry K Kvols
1 reference
Kjell E Oberg
1 reference
Pharis Mohideen
1 reference
Rudolf Arnold
1 reference
Ke Hu
1 reference
Yilong Zhang
1 reference
Gareth Hughes
1 reference
Lowell Anthony
1 reference
Bertram Wiedenmann
1 reference
14 September 2012
1 reference
1 reference
19
1 reference
657-666
1 reference
5
1 reference
Identifiers
1 reference
1 reference